Table 6 Meta-analysis for the association of NFKB-related polymorphisms and relative change of DAS28 score (∆DAS28).

From: NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium

Gene

SNP ID

Chr.

Effect allele

Discovery population (n = 604)

Replication DREAM registry (n = 882)

Replication DANBIO Registry (n = 621)

Meta-analysis (n = 2107)

OR (95% CI)∂

P

OR (95% CI)∂

P

OR (95% CI)∂

P

OR (95% CI)∂

P

I2

GBP6

rs928655

1

A

1.05 (0.87–1.27)

0.61

0.90 (0.80–1.00)

0.058

ND

ND

0.95 (0.82–1.10)

0.52

0.17

IKBKB

rs11986055

8

A

0.74 (0.48–1.11)

0.14

0.85 (0.66–1.07)

0.17

0.94 (0.64–1.39)

0.76

0.85 (0.71–1.02)

0.074

0.71

IRF4

rs1050975

6

A

0.95 (0.72–1.24)

0.69

0.99 (0.83–1.17)

0.87

1.24 (0.94–1.65)

0.13

1.03 (0.90–1.18)

0.67

0.33

IRF4

rs12203592

6

T

1.01 (0.77–1.33)

0.93

ND

ND

ND

ND

ND

ND

ND

IRF4

rs1877175

6

T

1.09 (0.90–1.33)

0.37

0.92 (0.82–1.13)*

0.15

0.90 (0.75–1.09)

0.30

0.96 (0.86–1.07)

0.47

0.31

IRF4

rs7768807

6

T

0.86 (0.72–1.03)

0.10

1.04 (0.93–1.16)*

0.52

ND

ND

0.96 (0.80–1.15)

0.65

0.08

KLRC1

rs7301582

12

T

1.05 (0.86–1.27)

0.62

1.00 (0.88–1.12)

0.94

0.99 (0.80–1.22)

0.92

1.00 (0.92–1.11)

0.85

0.90

KLRK1 | KLRC4

rs1049174

12

C

1.08 (0.91–1.29)

0.37

0.96 (0.86–1.08)

0.53

1.07 (0.90–1.27)

0.47

1.01 (0.93–1.10)

0.79

0.42

KLRK1 | KLRC4

rs1154831

12

A

0.89 (0.73–1.10)

0.28

1.05 (0.93–1.19)*

0.40

ND

ND

0.99 (0.84–1.16)

0.88

0.18

KLRK1 | KLRC4

rs2255336

12

A

1.09 (0.90–1.33)

0.38

1.01 (0.89–1.16)

0.81

ND

ND

1.04 (0.93–1.15)

0.54

0.53

LOC105376246

rs2722824

9

A

1.03 (0.86–1.23)

0.77

0.94 (0.85–1.05)

0.32

ND

ND

0.96 (0.88–1.05)

0.41

0.39

NFKB1

rs4648110

4

A

1.07 (0.88–1.29)

0.51

1.00 (0.89–1.13)*

0.95

ND

ND

1.02 (0.92–1.13)

0.71

0.56

NFKB2

rs11574851

10

T

0.97 (0.73–1.29)

0.83

0.92 (0.72–1.18)*

0.53

0.78 (0.57–1.06)

0.11

0.90 (0.76–1.05)

0.18

0.57

NFKB2

rs12769316

10

T

0.92 (0.75–1.13)

0.43

ND

ND

0.86 (0.70–1.06)

0.16

0.89 (0.77–1.03)

0.12

0.65

NFKB2 | PSD

rs1056890

10

T

1.22 (1.03–1.44)

0.025

1.08 (0.98–1.19)

0.11

1.31 (1.10–1.57)

0.0030

1.18 (1.05–1.33)

0.0077

0.12

NFKBIB

rs3136645

19

C

0.90 (0.73–1.11)

0.34

ND

ND

ND

ND

ND

ND

ND

NLRP3

rs4612666

1

T

1.05 (0.87–1.25)

0.62

1.20 (1.05–1.37)*

0.006

0.96 (0.80–1.14)

0.62

1.08 (0.94–1.23)

0.28

0.13

REL

rs13031237

2

T

1.07 (0.91–1.26)

0.40

1.03 (0.94–1.14)

0.49

1.08 (0.92–1.28)

0.36

1.05 (0.97–1.13)

0.21

0.86

REL

rs842647

2

A

1.03 (0.86–1.24)

0.72

0.96 (0.87–1.06)

0.45

ND

ND

0.98 (0.89–1.06)

0.57

0.51

REL

rs13017599

2

A

1.07 (0.91–1.27)

0.41

1.03 (0.94–1.14)

0.50

1.03 (0.86–1.21)

0.78

1.04 (0.96–1.12)

0.33

0.92

RELA

rs11820062

11

T

1.07 (0.90–1.26)

0.45

0.92 (0.84–1.01)*

0.081

ND

ND

0.98 (0.84–1.13)

0.74

0.12

RELA

rs2306365

11

A

0.91 (0.71–1.16)

0.45

1.19 (1.03–1.37)

0.021

ND

ND

1.06 (0.82–1.38)

0.66

0.064

RELA

rs7119750

11

T

0.93 (0.73–1.18)

0.54

ND

ND

ND

ND

ND

ND

ND

TLR10

rs11096957

4

A

1.00 (0.85–1.19)

0.98

0.99 (0.89–1.09)

0.80

ND

ND

0.99 (0.91–1.08)

0.87

0.92

TLR4

rs4986791

9

T

1.15 (0.78–1.70)

0.47

1.18 (0.98–1.41)*

0.077

ND

ND

1.18 (1.00–1.39)

0.056

0.91

TLR5

rs5744174

1

C

0.99 (0.83–1.17)

0.89

ND

ND

ND

ND

ND

ND

ND

TLR9 | | TWF2

rs187084

3

T

1.02 (0.86–1.21)

0.81

0.98 (0.88–1.08)*

0.67

ND

ND

0.99 (0.91–1.08)

0.83

0.69

TRAF1 | | C5

rs3761847

9

A

1.08 (0.91–1.29)

0.37

1.05 (0.95–1.16)

0.33

ND

ND

1.04 (0.96–1.14)

0.35

0.77

  1. Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
  2. A random effect model was assumed for the meta-analysis of both cohorts.
  3. ∂Estimates calculated according to an additive model of inheritance and adjusted for age, sex and country of origin (or age and sex in the replication stages).
  4. *Estimates based on imputed genotypes. P < 0.05 in boldface. No significant heterogeneity (heterogeneity chi-squared) was observed in any meta-analysis reported above.
Back to article page